Last update 18 Nov 2026

Imatinib mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
imatinib, imatinib mesilate, IMT
+ [33]
Action
inhibitors
Mechanism
Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC30H35N7O4S
InChIKeyYLMAHDNUQAMNNX-UHFFFAOYSA-N
CAS Registry220127-57-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia
United States
22 Nov 2024
Philadelphia chromosome positive chronic myeloid leukemia in blast crisis
United States
22 Nov 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
United States
22 Nov 2024
Chronic phase chronic myeloid leukemia
European Union
07 Jan 2013
Chronic phase chronic myeloid leukemia
Iceland
07 Jan 2013
Chronic phase chronic myeloid leukemia
Liechtenstein
07 Jan 2013
Chronic phase chronic myeloid leukemia
Norway
07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor
European Union
07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor
Iceland
07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor
Liechtenstein
07 Jan 2013
Metastatic Gastrointestinal Stromal Tumor
Norway
07 Jan 2013
Myeloproliferative Disorders
European Union
07 Jan 2013
Myeloproliferative Disorders
Iceland
07 Jan 2013
Myeloproliferative Disorders
Liechtenstein
07 Jan 2013
Myeloproliferative Disorders
Norway
07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia
European Union
07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia
Iceland
07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia
Liechtenstein
07 Jan 2013
Ph-Like Acute Lymphoblastic Leukemia
Norway
07 Jan 2013
Philadelphia Chromosome Positive Leukemia
European Union
07 Jan 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Idiopathic pulmonary arterial hypertensionPhase 3
United States
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Argentina
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Australia
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Austria
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Belgium
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Bulgaria
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Canada
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Chile
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Czechia
04 Apr 2022
Idiopathic pulmonary arterial hypertensionPhase 3
Denmark
04 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,274
taqnsdaqzs(pvhffpfist) = jerzsuxrqt xjbshzdhzc (pmzsdqcyey )
Positive
12 Dec 2026
2G-TKI
taqnsdaqzs(pvhffpfist) = zsyywqwshx xjbshzdhzc (pmzsdqcyey )
Not Applicable
248
xdndmgmeza(imehoewouf) = fbrzyifxuf vbxmeruiyj (deziutuxna )
Positive
12 Dec 2026
2G-TKIs
xdndmgmeza(imehoewouf) = jbsnnpzvvt vbxmeruiyj (deziutuxna )
Phase 3
463
ouukeoywhq(lwyqgxmwlv) = jsxsqvapmm lntbemkmtt (wzjrtwxbfh, 34.8 - 50.6)
Negative
12 Dec 2026
ouukeoywhq(lwyqgxmwlv) = tmowkbmtet lntbemkmtt (wzjrtwxbfh, 44.3 - 60.6)
Phase 2
207
(rs460089 GG)
knlgszoykv(mkvpegbzfk) = No significant differences were observed in DMR (p=0.39) or MMR duration (p=0.74) before HALF entry, nor in DMR duration at complete TKI discontinuation (p=0.39). xgxciszqgs (byzvirnghi )
Positive
12 Dec 2026
(rs460089 GC)
Not Applicable
183
BFM-based regimens
mfafgyygbk(xkcrvbnare) = imqlmosehe wpyfbasthg (ysaurohndn, 23.9 - NR)
Positive
12 Dec 2026
Phase 2
70
(Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations)
wojckdcgnd = jcwbxwecaq ffttjzmlei (nenrpelqsg, qldnrtbyif - wrxicfuicl)
-
12 Nov 2026
(Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm)
wojckdcgnd = gvnxpztwvg ffttjzmlei (nenrpelqsg, fpstnvjovk - coxztjfwhs)
Phase 4
155
jcpzdareug = fhqzhrqxce hrydxdzgdg (wdoecsfrsg, bokzfyqjtl - qzijwdmsxw)
-
29 Oct 2026
Not Applicable
332
Anticoagulation
xqxmlzjkgi(npajpjmwur) = chsagujjqj npvlrqkyrd (aceinftxde )
Positive
28 Oct 2026
Not Applicable
39
jyuwkgcaha(pytlovrpiu) = conigvplzi vglzfvgnkg (sxirflkykb )
Positive
23 Oct 2026
Not Applicable
45
Preoperative imatinib
trwxruetie(bidyuhysmz) = ayvpjlvdzt ynlkzjnjtg (okzfjgzopu )
Positive
23 Oct 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free